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A b s t r a c t
Background: Direct stent implantation is a preferred technique for primary percutaneous coronary intervention (PCI). For 
the deployment of a bioresorbable vascular scaffold (BVS), the current guidelines recommend aggressive predilatation. Data 
about direct BVS implantation in patients with acute coronary syndrome (ACS) are scarce.
Aim: We sought to assess procedural characteristics and immediate outcomes of direct Absorb BVS implantation in ACS patients.
Methods: A total of 91 patients with acute myocardial infarction (MI) requiring urgent coronary revascularisation were enrolled. 
Among them, 50 patients underwent an attempt of direct Absorb implantation. The control group consisted of 41 patients 
treated with PCI with BVS deployment after elective predilatation. 
Results: In the direct group BVS deployment was successful in 91% of lesions, and in the remaining 9% of lesions direct im-
plantation failed. In the control group scaffolds were successfully deployed after predilatation in 98% of lesions. In one case 
Absorb implantation failed even after balloon angioplasty. Type C lesions with severe tortuosity and angulation > 90° were 
associated with failure in direct Absorb deployment. Quantitative coronary analysis showed similar final percentages of diameter 
stenosis in the study and control groups. Flow analyses did not show significant differences between both methods. During 
hospitalisation no recurrent MI, scaffold thrombosis, or target lesion revascularisation was reported in either group.
Conclusions: Direct Absorb implantation in ACS patients may be feasible in a suitable lesion anatomy.
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INTRODUCTION
Absorb is an everolimus-eluting bioresorbable vascular scaf-
fold (BVS; Abbott Vascular, Santa Clara, CA, USA). Current 
recommendation for BVS implantation is plaque preparation 
with adequate predilatation [1, 2]. On the other hand, in the 
setting of large thrombus burden, aggressive predilatation 
may result in an increased risk of distal embolisation and 
subsequent flow deterioration [3]. There are scarce data in 
terms of the feasibility and safety of direct stenting with Ab-
sorb BVS [4, 5]. So far, there has been no specific evaluation 
of this approach in patients presenting with acute coronary 
syndrome (ACS). The aim of the current study was to assess 
procedural characteristics and angiographic results of direct 
BVS deployment in ACS patients. 
METHODS
Study population and procedure
The presented single-centre study is an analysis of 91 patients 
with acute myocardial infarction (MI) treated with primary 
percutaneous coronary intervention (PCI) with Absorb BVS 
implantation. A total of 50 patients underwent an attempt of 
direct Absorb implantation. The control group consisted of 
41 patients treated with PCI with Absorb deployment after 
elective predilatation. Angiographic data were assessed by an 
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independent core laboratory. The study was approved by the 
Institutional Board of Ethics. Inclusion criteria comprised acute 
MI and referral for primary PCI with BVS implantation after 
a diagnostic coronary angiography. All procedures were car-
ried out by three experienced operators (more than 1000 PCIs 
in ACS each). The decision whether to perform direct implan-
tation of the Absorb or to precede it with balloon angioplasty 
was made by the operator after careful examination of the 
culprit lesion anatomy. The sizes of the chosen scaffolds and 
balloons for predilatation and postdilatations, inflation pres-
sures, and the use of manual aspiration thrombectomy cath-
eters as well as additional imaging tools such as intravascular 
ultrasonography (IVUS) or optical coherence tomography 
(OCT) were also left to the operator’s discretion.
Angiographic assessment
All collected angiograms were sent to an independent Core 
Laboratory (KCRI, Krakow, Poland) and were examined by 
an analyst with experience in the evaluation of different bi-
oresorbable platforms. Qualitative and quantitative analyses 
were performed using CAAS V 2.1.12.2 software (Pie Medical, 
Maastricht, Netherlands). Standard stent parameters were 
analysed: minimal lumen diameter, reference vessel diameter 
(RVD), per cent diameter stenosis (%DS), acute gain, and 
acute recoil. The following angiographic flow parameters 
were examined before and after PCI of the infarct-related 
artery: epicardial antegrade flow using the Thrombolysis In 
Myocardial Infarction (TIMI) scale and corrected TIMI frame 
counts (cTFC) using standard landmarks for each artery. The 
American College of Cardiology/American Heart Association 
classification was used to define the lesions’ anatomy [6].
Statistical analysis
Quantitative variables were presented using mean and stand-
ard deviation (for normal distribution of data) or median with 
interquartile range (for non-normal distribution of data), where 
applicable. Categorical variables were presented as numbers 
and percentages. The Mann-Whitney U test (for non-normal 
distribution of data) or unpaired (two-sample) Student t test 
(for normally distributed data) were applied for continuous 
variables. The c2 test was used for categorical (nominal and 
dichotomous) variables. The level of statistical significance 
was set at p-value < 0.05. All analyses were performed with 
SPSS Statistics 24 (IBM, Inc., Armonk, NY, USA).
RESULTS
Clinical data are shown in Table 1. Most of the patients 
were male, and the most common clinical presentation was 
non-ST-segment elevation MI (NSTEMI). There were no signifi-
cant differences in demography and coronary artery disease 
risk factors between both groups (Table 1). Baseline angio-
graphic analysis showed no significant differences in lesion 
length, RVD, and %DS between the direct and predilatation 
groups. However, type C lesions with severe calcifications 
were more common in the predilatation arm. In the direct 
group, total occlusion and thrombus in target lesion were 
more frequent (Table 2). Absorb deployment was successful 
in 91% of lesions in this group. In the remaining 9% of lesions 
direct implantation failed. In these cases, the system was gently 
retrieved and inserted again within a relatively short period 
of time (max 2 min) after predilatation. In the control group 
scaffolds were successfully implanted in 98% of lesions. In 
one patient the delivery of Absorb scaffold was unsuccessful 
even after balloon preparation. In this case a regular metallic 
drug-eluting stent (DES) was successfully deployed. Type C 
lesions with severe tortuosity and angulation > 90° were as-
sociated with failure in direct Absorb deployment (Table 3).
During PCI, the use of extra-support coronary wires was 
more frequent in the predilatation arm. Postdilatation was 
performed in 94% of lesions from the direct group and in 79% 
of lesions from the predilatation arm (p = 0.04). Mean post-
dilatation pressure was 18 atm in both groups. Thrombectomy 
was performed in 48% of cases in the direct group and 13% of 
cases in the predilatation arm (p < 0.001). Predilatation with 
a small-size balloon (1.5 or 2.0 mm) for initial opening of the 
artery was performed in 17% of cases in the predilatation arm. 
Table 1. Demographic and baseline clinical characteristics
Direct (50 patients) Predilatation (41 patients) p
Age [years] 60 ± 10 60 ± 12 0.8
Male sex 38 (76) 36 (88) 0.2
STEMI 19 (38) 12 (29) 0.5
LVEF [%] 55 (Q1: 45; Q3: 60) 55 (Q1: 47; Q3: 60) 0.5
Previous PCI 2 (4) 4 (10) 0.4
Hypertension 32 (64) 23 (56) 0.5
Hyperlipidaemia 29 (58) 20 (49) 0.4
Diabetes 11 (22) 5 (12) 0.3
Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range). LVEF — left ventricular ejection fraction; 
PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction
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In the direct implantation group the procedural and radiation 
times were significantly shorter and the amount of contrast and 
radiation dose were significantly lower, compared to patients 
from the conventional scaffold implantation group (Table 4). 
Final flow analysis did not show significant differences 
between both groups, TIMI 3 flow grade was achieved in 
98% of cases in the direct arm and in 94% of cases in the 
predilatation group. There was no difference in final cTFC 
between both groups. No-reflow occurred in one case from 
the predilatation group. Slow-flow occurred in two patients 
from the direct implantation arm and in two patients from the 
predilatation arm. Acute gain was significantly higher in the 
direct group. There were no significant differences in terms 
of dissection complications, side branch occlusion, and em-
bolisation (Table 5). STEMI patients presented higher baseline 
%DS, with more frequent total occlusion and thrombus in the 
target lesion and also higher acute gain and lower %DS after 
PCI compared to NSTEMI patients (Table 6).
During hospitalisation no recurrent MI, scaffold throm-
bosis, or target lesion revascularisation was reported in 
either group.
DISCUSSION 
Initially, in the metallic stent era, balloon predilatation was 
a mandatory procedure before stent deployment. However, 
aggressive predilatations carry additional risk of plaque disrup-
tion, thrombus mobilisation, and distal embolism with subse-
quent flow deterioration [3]. Despite restoration of epicardial 
blood flow, tissue reperfusion often remains suboptimal. Over 
the years, mechanical and pharmacological strategies have 
been developed to increase myocardial salvage during PCI, 
including direct stenting, mesh-covered stents, thrombectomy, 
and glycoprotein IIb/IIIa inhibitors [3]. Several studies showed 
that direct stent implantation is associated with the reduction 
of flow disturbances after primary PCI, better ST-segment 
resolution as well as better survival at 30 days and one year 
Table 2. Baseline angiographic characteristics 
Direct (53 lesions) Predilatation (48 lesions) p
Left anterior descending location 20 (38) 23 (48) 0.3
Type C lesion 7 (13) 16 (33) 0.016
Severe tortuosity 5 (9) 6 (12) 0.7
Severe calcifications 0 (0) 5 (10) 0.018
Angulation > 90° 5 (9) 6 (12) 0.7
Lesion length [mm] 13.3 (Q1: 10; Q3: 16) 15.7 (Q1: 11; Q3: 21) 0.3
Minimal lumen diameter [mm] 0.65 (Q1: 0; Q3: 1.03) 0.78 (Q1: 0.13; Q3: 1.16) 0.1
Reference vessel diameter [mm] 2.8 ± 0.5 2.7 ± 0.6 0.3
Diameter stenosis [%] 78 (Q1: 59; Q3: 100) 67 (Q1: 54; Q3: 94) 1.0
Corrected TIMI frame count 100 (Q1: 30; Q3: 100) 30 (Q1: 24; Q3: 100) 0.02
Total occlusion 24 (45) 11 (23) 0.018
Thrombus in target lesion 34 (64) 15 (31) 0.001
Data are presented as percentage (number), mean ± standard deviation, or median (interquartile range). TIMI — Thrombolysis in Myocardial 
Infarction
Table 3. Lesion characteristics in groups with successful and failed direct Absorb deployment
Successful (48 lesions) Failed (5 lesions) p
Type C lesion 4 (8) 3 (60) 0.013
Severe tortuosity 2 (4) 3 (60) 0.004
Angulation > 90° 2 (4) 3 (60) 0.004
Irregular contour 24 (29) 1 (20) 1.0
Eccentric shape 16 (33) 1 (20) 1.0
Total occlusion 21 (44) 3 (60) 0.6
Thrombus in target lesion 31 (64) 3 (60) 1.0
Data are presented as number (percentage).
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Table 4. Procedural characteristics of percutaneous coronary intervention with Absorb deployed directly and after predilatation
Direct (48 lesions) Predilatation (52 lesions) p
Radial access 31 (65) 31 (60) < 0.001
Procedure time [min] 28 ± 11 40 ± 19 0.003
Fluoroscopy time [min] 9.6 ± 5.3 13.9 ± 8 0.006
Contrast dye used [mL] 126 ± 66 163 ± 77 0.006
Radiation dose [Gy] 1.08 ± 0.72 1.33 ± 0.62 0.039
Glycoprotein IIb/IIIa antagonists 19 (39) 14 (27) 0.2
Number of coronary wires 1.23 ± 0.42 1.7 ± 1.0 0.01
Extra-support coronary wires 1 (2) 14 (27) < 0.001
Additional back-up catheters 23 (48) 26 (50) 1.0
Scaffold length [mm] 18 (Q1: 18; Q3: 23) 23 (Q1: 18; Q3: 28) 0.016
Scaffold diameter [mm] 3.5 (Q1: 3; Q3: 3.5) 3.0 (Q1: 3; Q3: 3,5) 0.1
Scaffold implantation pressure [atm] 14 (Q1:12; Q3: 16) 14 (Q1: 12; Q3: 16) 0.4
Postdilatation balloon diameter [mm] 3.6 (Q1: 3.2; Q3: 4) 3.5 (Q1: 3.2; Q3: 4) 0.3
Postdilatation pressure [atm] 18 (Q1: 16; Q3: 20) 18 (Q1: 16; Q3: 20) 0.3
Thrombectomy 23 (48) 7 (13) < 0.001
Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range).
Table 5. Final angiographic results of percutaneous coronary intervention with Absorb implanted directly and after predilatation
Direct (48 lesions) Predilatation (52 lesions) p
Acute gain [mm] 1.89 ± 0.7 1.59 ± 0.7 0.036
Acute recoil [mm] 0.32 ± 0.23 0.29 ± 0.20 0.8
Diameter stenosis [%] 12.2 ± 6.1 12.7 ± 7.6 0.7
TIMI 3 flow grade 47 (98) 49 (94) 0.5
Corrected TIMI frame count 16 (Q1: 12; Q3: 22) 18 (Q1: 14; Q3: 24) 0.3
Slow-flow 2 (4) 2 (4) 1.0
No-reflow 0 (0) 1 (2) 1.0
Side branch occlusion 1 (2) 1 (2) 1.0
Side branch embolisation 1 (2) 1 (2) 1.0
Distal embolisation 0 (0) 1 (2) 1.0
Dissection 3 (6) 8 (15) 0.2
Bail-out stenting 2 (4) 6 (12) 0.3
Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range). TIMI — Thrombolysis in Myocardial 
Infarction
Table 6. Differences between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial 
infarction (NSTEMI) groups
STEMI (36 lesions) NSTEMI (65 lesions) p
Type C lesions 8 (22) 15 (23) 1.0
Thrombus in target lesion 26 (72) 24 (35) 0.002
Total occlusion 22 (61) 13 (20) < 0.001
Baseline diameter stenosis [%] 100 (Q1: 72; Q3: 100) 64 (Q1: 54; Q3: 83) < 0.001
Final diameter stenosis [%] 10 ± 7 13 ± 7 0.036
Final TIMI 3 flow grade 34 (94) 62 (95) 1.0
Acute gain [mm] 2.1 ± 0.6 1.6 ± 0.7 < 0.001
Acute recoil [mm] 0.32 ± 0.20 0.30 ± 023 0.8 
Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range). TIMI — Thrombolysis in Myocardial 
Infarction
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[7–10]. Another strategy designed to reduce distal embolisa-
tion is the use of a MGuard™ bare metal mesh-covered stent, 
which traps the potentially embolic material at the level of 
the culprit lesion. However, the use of mesh-covered stents 
is limited due to lack of anti-proliferative drugs. They should 
also be avoided in bifurcation and highly tortuous or calci-
fied lesions [3, 11]. Routine thrombectomy is currently not 
recommended in primary PCI, but in the presence of large 
thrombotic burden it may be considered, also with the direct 
stenting technique [12, 13]. Glycoprotein IIb/IIIa inhibitors are 
strong antiplatelet agents, which could be used in patients with 
high risk of ischaemic events (large thrombotic burden) and 
angiographic complications (distal embolisation, no-reflow 
phenomenon) [14]. 
Currently, direct DES implantation is a preferable tech-
nique for primary PCI in the ACS setting in suitable coronary 
anatomy. However, the permanent metallic platform of 
regular DESs also has some limitations, including impaired 
vasomotion, reduced potential for vessel remodelling, chronic 
inflammation processes, and late thrombosis [15]. BVSs were 
designed to target the limitations of regular DESs with restored 
vasomotion, arterial remodelling, and late lumen enlargement 
[16, 17]. Nevertheless, recent data show inferiority of Absorb 
BVS, compared to regular DES, with higher rates of scaffold 
thrombosis (probably due to late scaffold discontinuity lead-
ing to disruption of laminar flow), possible thrombogenicity 
of breakdown products, and local inflammation processes 
occurring after resorption of the scaffold [18]. Data from two 
studies, ABSORB III and AIDA, showed higher rates of prob-
able/definite scaffold thrombosis in the BVS group compared 
to the everolimus-eluting stent arm at one and two years of 
follow-up [19, 20]. Results of the ABSORB II study showed 
that vasomotor reactivity after three years was not significantly 
different from the regular DES arm; also, the late lumen loss 
was greater in the Absorb group [21]. Currently Absorb is not 
recommended in regular clinical use [18]. A Polish consensus 
statement on bioresorbable scaffolds also advised against the 
use of Absorb in routine practice [22]. On the other hand, 
other scaffolds built of polylactic acid and magnesium have 
the same strut thickness as the Absorb and are approved for 
clinical use; therefore, we think that the presented analysis 
is currently relevant. Nevertheless, a new generation of BVSs 
with thinner struts and rounder strut cross-section, minimis-
ing flow disturbances is being sought. The current Absorb 
generation presents struts of 152 μm and a crossing profile of 
1.4 mm. Due to increased strut thickness, larger crossing pro-
file, and the device’s lower penetrating force into the plaque, 
predilatation was recommended before scaffold deployment. 
Data about direct BVS implantation technique are scarce. In 
earlier studies, direct stenting with Absorb was performed, 
ranging from 9% in a Polish registry to 44% in a randomised 
TROFI trial [23, 24]. In a Spanish study that included both 
stable coronary artery disease and ACS patients, direct scaf-
fold implantation was attempted in 150 lesions [4]. Successful 
BVS delivery was achieved in 86% of cases in the direct arm. 
Longer, C-type lesions and a larger plaque burden were as-
sociated with failure in Absorb implantation in that analysis [4]. 
Another study included a retrospective overview of nine 
ACS patients treated with direct BVS implantation. Scaffolds 
were successfully implanted in all patients [5]. In our analysis 
type C lesions with severe tortuosity and angulation > 90° 
were associated with failure in direct Absorb deployment.
Outcomes of Absorb implantation vary depending on 
the centre’s and operator’s experience, implantation tech-
nique, and use of intravascular imaging tools [25]. Standard 
BVS-specific implantation protocol includes predilatation 
with a non-compliant balloon up to the size of the RVD, 
implantation of the Absorb of the same size as the RVD, and 
high-pressure postdilatation for optimal scaffold apposition, 
with a non-compliant balloon of the same diameter as the 
RVD or 0.5 mm larger [26, 27]. On the other hand, overexpan-
sion might lead to strut fracture, so the size of the postdilata-
tion balloon should not exceed the scaffold diameter by more 
than 0.5 mm. For this reason, precise vessel/scaffold sizing 
should be performed, preferably with OCT, which also allows 
accurate assessment of scaffold apposition [22]. Optimal vessel 
selection is also important, as an RVD of < 2.25 mm has been 
identified as a predictor of scaffold thrombosis after Absorb 
implantation [19]. However, due to limited availability and 
high costs, OCT is generally underused. In our registry, only 
visual estimations were applied, which is a typical clinical 
approach in the ACS all-comer populations. In the presented 
study scaffolds were implanted by highly skilled operators 
with experience in BVS implantation in both ACS and stable 
coronary disease patients, with use of IVUS and OCT, and 
the BVS-specific implantation protocol with high-pressure 
postdilatation was implemented. The median postdilatation 
balloon diameter was 3.6 mm in the direct group and 3.5 mm 
in the predilatation group, whereas baseline reference vessel 
diameters were 2.8 and 2.7 mm, respectively. Median scaf-
fold diameter was 3.5 mm in the direct group and 3.0 mm 
in the predilatation arm. 
The most important finding of the presented analysis is 
the feasibility and good immediate angiographic results of 
direct BVS deployment in patients with acute MI. Our registry 
shows that the procedure of BVS implantation can be effective 
in a suitable lesion anatomy. Successful Absorb implantation 
was achieved in 91% of cases in the direct arm and 98% of 
cases in the predilatation group. 
The presented analysis was a registry, not a randomised 
study, but it represents real-world data. The registry sample 
size is relatively small and the results only allow for hypoth-
esis generation and possible planning of larger randomised 
studies. The methods used in this study were suboptimal. 
The presented procedural results were based on angiography 
and quantitative analysis. The use of IVUS or OCT was not 
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obligatory and the decision whether to use it was left to the 
operator. The value of an angiographic assessment of a scaf-
fold invisible for fluoroscopy is limited and does not provide 
information about the scaffold apposition. Finally, frequent 
use of guiding catheters as an additional back-up could have 
contributed to the high success rates in BVS deliverability in 
our analysis.
In conclusion, direct Absorb implantation in patients with 
acute MI may be effective and feasible in suitable coronary 
anatomy. 
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